Immunogenicity of the pentavalent rotavirus vaccine in African infants (Q47832209)

6 February 2018

title

Immunogenicity of the pentavalent rotavirus vaccine in African infants. (English)

1 reference

6 February 2018

Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe

0 references

0 references

0 references

0 references

1 reference

2

Robert F Breiman

Breiman, R.F.

1 reference

6 February 2018

9

Max Ciarlet

1 reference

6 February 2018

Samba Sow

7

object named as

Samba O Sow

1 reference

6 February 2018

Kathleen Neuzil

5

object named as

Kathleen M Neuzil

1 reference

6 February 2018

author name string

George E Armah

1

1 reference

6 February 2018

Milagritos D Tapia

3

1 reference

6 February 2018

Michael J Dallas

4

1 reference

6 February 2018

Fred N Binka

6

1 reference

6 February 2018

Joel Ojwando

8

1 reference

6 February 2018

A Duncan Steele

10

1 reference

6 February 2018

Armah, G.E.

0 references

Tapia, M.D.

0 references

Dallas, M.J.

0 references

Neuzil, K.M.

0 references

Binka, F.N.

0 references

Ojwando, J.

0 references

Ciarlet, M.

0 references

language of work or name

English

0 references

publication date

1 April 2012

1 reference

6 February 2018

2012

0 references

published in

Vaccine

1 reference

6 February 2018

volume

30 Suppl 1

1 reference

6 February 2018

page(s)

A86-93

1 reference

6 February 2018

http://ugspace.ug.edu.gh/handle/123456789/26886

exact match

0 references

cites work

Global, regional, and national causes of child mortality in 2008: a systematic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Rotavirus vaccines: targeting the developing world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Serum antibody as a marker of protection against natural rotavirus infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Influence of potential protective mechanisms on the development of live rotavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

The role of serum antibodies in the protection against rotavirus disease: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Development of an improved method for measuring neutralizing antibody to rotavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Rotavirus infection in infants as protection against subsequent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Oral rotavirus vaccines: how well will they work where they are needed most?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Oral tetravalent rotavirus vaccine can be successfully coadministered with oral poliovirus vaccine and a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine. US Rhesus Rotavirus Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.006

10.1016/J.VACCINE.2011.10.006

7 January 2021

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

22520142

1 reference

6 February 2018